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Research
AbstrACt
Objectives To estimate and compare the prevalence 
and type of potentially inappropriate prescribing (PIP) and 
potential prescribing omissions (PPOs) among community-
dwelling older adults (≥65 years) enrolled to a clinical trial 
in three European countries.
Design A secondary analysis of the Thyroid Hormone 
Replacement for Subclinical Hypothyroidism Trial dataset.
Participants A subset of 48/80 PIP and 22/34 PPOs 
indicators from the Screening Tool of Older Persons 
Prescriptions/Screening Tool to Alert doctors to Right 
Treatment (STOPP/START) V2 criteria were applied to 
prescribed medication data for 532/737 trial participants 
in Ireland, Switzerland and the Netherlands.
results The overall prevalence of PIP was lower in 
the Irish participants (8.7%) compared with the Swiss 
(16.7%) and Dutch (12.5%) participants (P=0.15) and 
was not statistically significant. The overall prevalence 
of PPOs was approximately one-quarter in the Swiss 
(25.3%) and Dutch (24%) participants and lower in the 
Irish (14%) participants (P=0.04) and the difference 
was statistically significant. The hypnotic Z-drugs 
were the most frequent PIP in Irish participants, (3.5%, 
n=4), while it was non-steroidal anti-inflammatory 
drug and oral anticoagulant combination, sulfonylureas 
with a long duration of action, and benzodiazepines 
(all 4.3%, n=7) in Swiss, and benzodiazepines (7.1%, 
n=18) in Dutch participants. The most frequent PPOs 
in Irish participants were vitamin D and calcium in 
osteoporosis (3.5%, n=4). In the Swiss and Dutch 
participants, they were bone antiresorptive/anabolic 
therapy in osteoporosis (9.9%, n=16, 8.6%, n=22) 
respectively. The odds of any PIP after adjusting for 
age, sex, multimorbidity and polypharmacy were 
(adjusted OR (aOR)) 3.04 (95% CI 1.33 to 6.95, P<0.01) 
for Swiss participants and aOR 1.74 (95% CI 0.79 to 
3.85, P=0.17) for Dutch participants compared with 
Irish participants. The odds of any PPOs were aOR 2.48 
(95% CI 1.27 to 4.85, P<0.01) for Swiss participants 
and aOR 2.10 (95% CI 1.11 to 3.96, P=0.02) for Dutch 
participants compared with Irish participants.
Conclusions This study has estimated and compared the 
prevalence and type of PIP and PPOs among this cohort 
of community-dwelling older people. It demonstrated a 
significant difference in the prevalence of PPOs between 
the three populations. Further research is urgently 
needed into the impact of system level factors as this 
has important implications for patient safety, healthcare 
provision and economic costs.
strengths and limitations of this study
 ► This is the first study to estimate and compare the 
prevalence and type of potentially inappropriate pre-
scribing (PIP) and potential prescribing omissions 
(PPOs) using a subset of the Screening Tool of Older 
Persons Prescriptions/Screening Tool to Alert doc-
tors to Right Treatment (STOPP/START) V2 criteria in 
community-dwelling older adults enrolled to a clin-
ical trial across three different European countries.
 ► The Thyroid Hormone Replacement for Subclinical 
Hypothyroidism Trial  (TRUST) database contains 
comprehensive information on patient demograph-
ics, comorbidities and medication, and this facilitat-
ed the assessment and measurement of prescribing 
commission and omission for participants included 
in the clinical trial.
 ► The sample size (n=532) and sampling scheme 
may limit insights about prescribing nationally in the 
three countries.
 ► It was only possible to apply a subset of the criteria 
to the database due to a lack of information on drug 
strength, dose and duration of prescriptions, and 
this may explain the low prevalence of PIP and PPOs 
in the study.
 ► Some countries may have specific guidelines for 
the optimal treatment of conditions; therefore, these 
guidelines could differ from the recommendations 
in the STOPP/START criteria and could explain why 
some PIP and PPOs were identified in one population 
and not in others.
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IntrODuCtIOn 
Older people often have multiple comorbidities and as 
a consequence are frequently prescribed multiple drugs. 
This increases their risk of adverse drug events, extended 
hospital stays and mortality.1 Potentially inappropriate 
prescribing (PIP) describes any drug that has the poten-
tial to cause an adverse event which can outweigh its 
clinical benefit compared with alternative treatment 
options.2 Appropriateness of prescribing in older people 
can be assessed using either implicit (judgement-based) 
or explicit (criterion-based) screening tools.3 Implicit 
tools require healthcare professionals to assess the appro-
priateness of prescribing based on clinical guidelines 
and each patient situation.3 Explicit tools are usually 
developed from published literature, expert opinion and 
consensus techniques.4 
In recent years, the Screening Tool of Older Persons 
Prescriptions/Screening Tool to Alert doctors to Right 
Treatment (STOPP/START) criteria were developed 
and validated as an explicit measure of PIP and potential 
prescribing omissions (PPOs) for use in older adults (≥65 
years) in European countries.5 All criteria are organised 
according to physiological systems for ease of use.6 In 2014, 
the STOPP/START criteria were revised and adapted to 
new evidence-based guidelines, STOPP/START version 2 
(STOPP/START V2), comprising 80 STOPP and 34 
START criteria. Several new STOPP categories created 
in V2 include antiplatelet/anticoagulant drugs, drugs 
affecting, or affected by, renal function and drugs that 
increase anticholinergic burden. New START categories 
include urogenital system drugs, analgesics and vaccines. 
A number of criteria from V1 were removed in V2 due to 
a lack of evidence from the published literature.7
A number of studies have reported the prevalence 
of PIP/PPOs in large populations of older adults using 
subsets of the STOPP/START V1 criteria. Cahir et al esti-
mated the prevalence of PIP was 36% among adults ≥70 
years in a primary care population in Ireland.8 In a similar 
study, Bradley et al reported a prevalence of PIP of 29% 
among older adults in primary care in the UK.9 Bruin-Hu-
isman et al estimated the prevalence of potentially inap-
propriate medicines (PIMs) and PPOs among older 
patients in primary care in the Netherlands. In this retro-
spective longitudinal study, the mean prevalence of ≥1 
PIMs and PPOs were 34.7% and 84.8%, respectively.10 
Urfer et al assessed the efficacy and safety of a prescriber 
checklist for reducing inappropriate prescribing among 
900 patients ≥65 years admitted to an internal ward of a 
Swiss hospital. The study reported that 37% of patients 
had ≥1 PIM while 25% had ≥1 PPO.11 However, there is a 
lack of research exploring the prevalence of PIP and PPOs 
in community-dwelling older adults using the updated 
criteria. For example, Blanco-Reina et al reported a prev-
alence of PIP and PPOs of 40.4% and 21.8%, respectively, 
among older adults in Spain.12 In a study conducted in 
Turkey, 667 participants aged ≥65 years were admitted 
to an outpatient clinic of a university hospital. The prev-
alence of PIP reported was 39.1%.13 A study conducted 
among 319 older patients discharged from a hospital in 
Albania identified that 63% received at least one PIP.14 
In another study carried out in Ethiopia, the prevalence 
of inappropriate prescribing of antithrombotic therapy 
among 156 hospitalised elderly patients was assessed. 
The prevalence of PIP and PPOs were 51.4% and 48.6%, 
respectively.15 Therefore, the aim of this study is to esti-
mate and compare the prevalence and type of PIP and 
PPOs among a sample of community-dwelling older 
adults enrolled to a clinical trial across three different 
European countries using a subset of the STOPP/START 
V2 criteria.
MethODs
study population
This is a secondary analysis of the Thyroid Hormone 
Replacement for Subclinical Hypothyroidism (TRUST) 
Trial dataset. The full study protocol has been previ-
ously published, and a summary is provided here.16 The 
trial was conducted in four countries (Ireland, Scotland, 
Switzerland and the Netherlands). Community-dwelling 
participants aged ≥65 years with untreated subclinical 
hypothyroidism (SCH) were identified from clinical labo-
ratory databases or by searching general practitioners’ 
(GPs’) databases/notes and were randomly assigned to 
levothyroxine or placebo. SCH was defined as persistently 
elevated thyroid stimulating hormone levels (4.6–19.9 
mU/L) with free thyroxine (fT4) within the local labora-
tory reference range.16 17
Medication information was available for three of the 
four countries (Ireland, Switzerland (one site, Bern) and 
the Netherlands). On enrolment to the study in Ireland 
and the Netherlands, participants self-reported their 
prescription medicines and medical history to the study 
nurses. In Ireland, this involved participants bringing 
their medicines or prescription and a list of their medical 
conditions to the study visit. In the Netherlands, the study 
visit was carried out in the participant’s home. In Switzer-
land, the study nurses received a list of the medical history 
and prescription medicines from the participant’s GP. 
When it was not possible to obtain either list, the partici-
pants self-reported their medical history and prescription 
medicines. If ambiguity occurred regarding the reporting 
of prescription medicines or medical history in any of the 
study sites, the participant’s GP or local pharmacy were 
contacted. The study nurses recorded all the participants’ 
prescribed medicines and entered them into an online 
electronic case report form (eCRF). Detailed information 
on participant demographics (date of birth, sex, race, 
smoking history, alcohol consumption), social circum-
stances (living arrangements, home support services, 
district nurse/public health nurse, informal caregiver), 
physical measurements (systolic and diastolic blood pres-
sure, heart rate, weight, height, waist circumference) and 
medical history was also collected. The data for this study 
were obtained following access to the secure eCRF on the 
TRUST web portal.16
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Application of the stOPP/stArt criteria
There have been significant changes to the updated 
criteria. Firstly, there are more criteria in V2 (80 STOPP 
and 34 START compared with 65 STOPP and 22 START 
in V1). Secondly, new drug groups have been included 
in the updated criteria, for example, sulfonylureas with 
a long duration of action. Thirdly, a number of criteria 
from V1 were removed from V2 due to a lack of evidence 
from the published literature. Twelve STOPP V1 criteria 
were removed from V2. Twenty-seven new criteria were 
introduced in STOPP V2, and 22 of these criteria were 
applied to the TRUST dataset. Three START V1 criteria 
were removed from V2, while 15 new criteria were 
introduced. Nine of these new criteria were applied to 
the TRUST dataset.18 The extra criteria included in V2 
arose from new clinical trial information, new system-
atic review information and expert panel suggestions 
for new criteria. This highlights the need to update and 
revise the criteria on a regular basis as some criteria 
can become outdated or obsolete. Also, new drugs have 
entered the market since the V1 criteria were validated 
in 2008.
A subset of the STOPP/START V2 criteria were 
applied, as information required for some criteria (ie, 
drug strength, dose and duration of prescriptions) was 
not available in the TRUST dataset. There was consensus 
among the study pharmacists (DOR, KW and SB) on 
the number and type of criteria selected, based on the 
ability to confidently apply the criteria to the data avail-
able. Therefore, 48 PIP indicators and 22 PPOs indica-
tors were applied (see online supplementary appendix 
1). Prescription drugs identified from the database were 
used as proxies to indicate a diagnosis of certain clinical 
conditions such as Parkinson’s disease, glaucoma and 
gout. For example, if a participant was prescribed colchi-
cine, this information was used as a proxy for a diagnosis 
for gout. This methodology has been used in previous 
studies.19 A coding scheme was then developed between 
DOR and KW. PIP and PPOs’ prevalence were estimated 
according to STOPP/START V2 and recorded in Micro-
soft Office Excel (2013). It was agreed a priori by the 
authors that DOR (research pharmacist) would manu-
ally apply the criteria to all the Irish, Swiss and Dutch 
data. For validation purposes, the criteria were applied 
independently by a second member of the research 
team. KW (research pharmacist) applied the criteria 
to a random 10% sample of the Irish and Dutch data. 
CEA (research medical doctor) applied the criteria to 
a random 10% sample of the Swiss data. There are two 
studies (OPERAM, SENATOR) currently assessing the 
automatisation of the STOPP/START criteria to identify 
PIP and PPOs in older people.20 21 The results from both 
studies should inform on the best method of automa-
tising screening tools to identify PIP and PPOs in this 
group of people. Therefore, the method used in this 
study for assessing the STOPP/START criteria should be 
considered as valid.
Outcomes
The main outcome of interest was the overall preva-
lence of any PIP or PPOs within participants from the 
TRUST trial in Ireland, Switzerland and the Netherlands 
according to a subset of the STOPP/START V2 criteria. 
Secondary outcome measures were (1) the prevalence 
of PIP and PPOs for each individual STOPP/START V2 
criterion; (2) the most common PIP and PPOs in each 
country and (3) the association between the explanatory 
variables country, age, sex, multimorbidity and polyphar-
macy and dependent variables PIP and PPOs.
statistical analysis
Data analyses were performed using StataV.13 (StataCorp, 
College Station, Texas, USA). Statistical significance was 
considered P<0.05. Characteristics of included partici-
pants were stratified by country. Continuous variables 
were presented as mean with SD and range, or median 
with IQR, as appropriate, and categorical variables as 
frequency (percentage). The overall prevalence of PIP/
PPOs was defined as the proportion of participants having 
at least one PIP or PPO according to the STOPP/START 
V2 criteria among all participants included in this analysis 
and was further stratified by country. The prevalence esti-
mates were compared using the χ2 test. Participants were 
further classified by sex and age group (65–74 years, ≥75 
years). Other explanatory variables included polyphar-
macy, defined as the concurrent use of five or more medi-
cations, and multimorbidity (co-occurrence of three or 
more chronic conditions).22 The association between 
age, sex, multimorbidity, polypharmacy and country with 
any PIP/PPOs (vs none) was assessed using multivariable 
logistic regression and presented as adjusted OR (aOR) 
with 95% CI and P values. Multicollinearity between the 
independent variables polypharmacy and multimorbidity 
was assessed by calculating the variance inflation factor 
(VIF). Sensitivity analysis excluding criteria triggered by 
combination of more than one drug was also performed.
standardised reporting guidelines
The Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) standardised 
reporting guidelines for cross-sectional studies have been 
followed to ensure the uniform conduct and reporting 
of the research (see online supplementary appendix 2).23
results
Population characteristics
The population characteristics of the 532 out of 737 
included TRUST participants are detailed in table 1. 
The mean age (±SD) of participants were 74.6 (5.9) in 
Ireland, 76.4 (5.9) in Switzerland and 76.1 (6.8) years in 
the Netherlands. The proportion of women varied across 
countries from 42.6% in Ireland and 46.3% in Switzer-
land to 65% in the Netherlands. Hypertension (which was 
defined from participants’ medical history) was the most 
common morbidity reported in each country (Ireland 
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65.2%, Switzerland 51.2%, the Netherlands 44.7%). 
The prevalence of the most common comorbidities in 
each country are also provided (see online supplemen-
tary appendix 3). The median number of drugs (IQR) 
prescribed to participants in each country was 4 (2–6).
Overall prevalence of PIP and PPOs in each country
The overall prevalence of PIP in the three populations 
was 12.9% (n=69). It was lower in the Irish participants 
(8.7%, n=10) compared with the Swiss (16.7%, n=27) and 
Dutch (12.5%, n=32) participants (P=0.15). In Ireland, 
7% (n=8) of participants had a single PIP compared with 
13.6% (n=22) of participants in Switzerland and 11.8% 
(n=30) of participants in the Netherlands. In Ireland, 
1.8% (n=2) of participants had two or more PIP compared 
with 3.1% (n=5) of participants in Switzerland and 0.8% 
(n=2) of participants in the Netherlands.
The overall prevalence of PPOs in the three populations 
was 22.2% (n=118). It was approximately one-quarter in 
the Swiss (25.3%, n=41) and Dutch (24%, n=61) partic-
ipants and lower in the Irish (14%, n=16) participants 
(P=0.04). In Ireland, 12.0% (n=14) of participants 
presented with one PPO compared with 15.4% (n=25) of 
participants in Switzerland and 13.7% (n=35) of partici-
pants in the Netherlands. In Ireland, 1.7% (n=2) of partic-
ipants presented with two or more PPOs compared with 
9.9% (n=16) of participants in Switzerland and 10.2% 
(n=26) of participants in the Netherlands.
the most common PIP in each country
Figure 1 shows the most common PIP in each population. 
The hypnotic Z-drugs (zopiclone, zolpidem, zaleplon) 
were the most frequent PIP in Irish participants with 
3.5% (n=4), followed by the prescribing of a beta blocker 
in participants diagnosed with bradycardia (<50/min), 
type II heart block or complete heart block with 1.7% 
(n=2). The most frequent PIP in the Swiss participants 
were (1) the combination of a non-steroidal anti-inflam-
matory drug (NSAID) with oral anticoagulants (4.3%, 
n=7); (2) sulfonylureas with a long duration of action 
(eg, glibenclamide, chlorpropamide, glimepiride) in 
participants with type 2 diabetes mellitus (4.3%, n=7) 
and (3) the prescribing of benzodiazepines (4.3%, n=7). 
The most frequent PIP in the Dutch participants was the 
prescribing of benzodiazepines (7.1%, n=18), followed 
by sulfonylureas with a long duration of action in partici-
pants with type 2 diabetes mellitus (2.4%, n=6).
the most common PPOs in each country
Figure 2 shows the most common PPOs in each popula-
tion. The most frequent PPOs in Irish participants were 
vitamin D and calcium supplements in participants with 
known osteoporosis and/or previous fragility fracture(s) 
(3.5%, n=4). The second most frequent PPOs were 
regular inhaled β2 agonists or antimuscarinic broncho-
dilators for mild to moderate asthma or chronic obstruc-
tive pulmonary disease (2.6%, n=3). The most frequent 
PPOs in the Swiss participants were bone antiresorptive 
or anabolic therapy (eg, bisphosphonate, strontium 
ranelate, teriparatide, denosumab) in participants with 
documented osteoporosis (9.9%, n=16). The second 
most frequent PPOs in the Swiss participants were anti-
platelet therapy with a documented history of coronary, 
cerebral or peripheral vascular disease (7.4%, n=12). 
The most frequent PPOs in the Dutch participants were 
bone antiresorptive or anabolic therapy in participants 
with documented osteoporosis (8.6%, n=22), followed by 
Table 1 Baseline characteristics
Population characteristics (n=532) Ireland Switzerland Netherlands P value
Number of patients, n (% of total population in study) 115 (21.6) 162 (30.5) 255 (47.9)
Mean age (years) (±SD), range 74.6 (5.9), 66–95 76.4 (5.9), 66–92 76.1 (6.8), 66–95 0.054
Females, n (%) 49 (42.6) 75 (46.3) 166 (65.1) <0.001
Current smokers, n (%) 5 (4.3) 12 (7.4) 24 (9.4) 0.02
Mean alcohol consumption (units per week) (±SD) 5.5 (9.4) 3.6 (4.9) 7.4 (10.3) 0.008
Living arrangements (co-habiting),* n (%) 77 (66.9) 91 (56.2) 161 (63.1) 0.021
Mean body mass index (±SD) 28.3 (4.3) 27.5 (4.9) 27.8 (4.8) 0.318
Most common morbidity, hypertension, n (%) 75 (65.2) 83 (51.2) 114 (44.7) 0.001
Median number of drugs prescribed per patient, IQR 4 (2,5) 4 (2,5) 4 (2,6) 0.828
Polypharmacy,† n (%) 51 (44.3) 60 (37.0) 106 (41.6) 0.447
Mean (±SD) EuroQol 5D: EQ Visual Analogue Scale 
score/100
82 (15.2) 82 (12.1) 76 (11.6) <0.001
Mean (±SD) Mini-Mental State Examination (/30) 28 (2.2) 28 (1.8) 29 (1.2) <0.001
Mean (± SD) ‡TRUST Barthel Index/22 22 (1.0) 22 (1.0) 22 (1.0) 0.010
*Living arrangements: whether participants were co-habiting or living alone.
†Polypharmacy: defined as five or more regular medicines.
‡An extra question was added under the heading ‘Bladder’: ‘does the participant have a urinary catheter?’
TRUST, Thyroid Hormone Replacement for Subclinical Hypothyroidism Trial. 
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prescribing omissions of vitamin D and calcium supple-
ment in participants with known osteoporosis and/or 
previous fragility fracture(s) (6.3%, n=16).
Factors associated with PIP
Table 2 shows the univariable and multivariable logistic 
regression analysis for the association between age, 
sex, multimorbidity and polypharmacy with PIP. In the 
univariable and multivariable models, there was no statis-
tically significant association between age or sex and PIP. 
However, the association between multimorbidity or poly-
pharmacy and PIP was statistically significant for both 
models.
Further analysis demonstrated that the odds of any 
PIP after adjusting for age, sex, multimorbidity and poly-
pharmacy were aOR 3.04 (95% CI 1.33 to 6.95, P<0.01) 
for Swiss participants and aOR 1.74 (95% CI 0.79 to 3.85, 
P=0.17) for Dutch participants compared with Irish 
participants.
Factors associated with PPOs
Table 3 shows the univariable and multivariable logistic 
regression analysis for the association between age, sex, 
multimorbidity and polypharmacy with PPOs. In the 
univariable model, the association between age or multi-
morbidity and PPOs was statistically significant. However, 
the association was not statistically significant for sex or 
polypharmacy. In the multivariable model, the association 
between sex or multimorbidity or age and PPOs was statis-
tically significant. However, the association was not statis-
tically significant for polypharmacy.
The odds of any PPOs after adjusting for age, sex, multi-
morbidity and polypharmacy were aOR 2.48 (95% CI 
1.27 to 4.85, P<0.01) for Swiss participants and aOR 2.10 
(95% CI 1.11 to 3.96, P=0.02) for Dutch participants 
compared with Irish participants.
The VIF for multimorbidity and polypharmacy were 
1.82 and 2.13, respectively. Sensitivity analysis excluding 
criteria triggered by combination of more than one drug 
had no effect on the study results.
DIsCussIOn
results in the context of the current literature
A systematic review of 13 research studies described the appli-
cation of the STOPP/START V1 criteria in different health-
care settings. The prevalence of PIP and PPOs ranged from 
21% to 79% and 23% to 74%, respectively.24 Studies reporting 
the prevalence of PIP and PPOs using the expanded STOPP/
START V2 criteria in large populations of older people are 
limited. The overall prevalence of PIP and PPOs in our study 
was lower compared with previous studies carried out in 
Spain, Turkey, Albania and Ethiopia.12–15 However, this may 
have been due to differences in number and type of criteria 
applied to the data and the population studied.
Figure 1 The most common types of potentially inappropriate prescribing in each country. AF, atrial fibrillation; CVD, 
cardiovascular disease; HF, heart failure; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; T2DM, 
type 2 diabetes mellitus.
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In this study, the prescribing of benzodiazepines was 
identified as a common PIP among Dutch (7.1%, n=18) 
and Swiss participants (4.32%, n=7). However, in Ireland, 
it was reported at <1% (n=1). These findings are in keeping 
with a recent panel survey in Ireland using patient-level 
dispensing data, highlighting that benzodiazepines were 
one of the few medicines without a yearly increase in 
prescribing between 1997 and 2012.25 In 2009 a nation-
wide programme was introduced in the Netherlands 
which aimed to reduce the prescribing rates of benzodiaz-
epines. Dutch GPs are required to state the indication for 
all benzodiazepines prescribed to allow patients apply for 
reimbursement of the medicine costs.26 In Switzerland, 
no similar programme exists. In Ireland, GPs receive a 
printout of their benzodiazepine prescribing from the 
General Medical Scheme (GMS). The GMS is a national 
tax-funded health insurance programme that provides 
access to medical and surgical services for low-income 
individuals/families and older people.27 This feedback 
highlights the prescribing practice of the GPs compared 
with their peers and allows them to carry out a clinical 
audit in this topic area. The audit also provides GPs with 
the necessary tools to identify best practice, and this may 
have impacted on the low prescribing of benzodiazepines 
in the study compared with the two other countries. This 
low prevalence could also be due to a difference in the 
sampling approach in Ireland or it may have occurred by 
chance.
Frequent PPOs across all three populations included 
vitamin D and calcium supplements in participants with 
Figure 2 The most common types of potential prescribing omissions in each country. * Unless the patient’s status is end-
of-life or age is >85 years. CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HF, heart failure; 
START, Screening Tool to Alert doctors to Right Treatment; VD, vascular disease.  
Table 2 Results of the univariable and multivariable logistic regression analyses for the association between age, sex, 
multimorbidity and polypharmacy with potentially inappropriate prescribing
Explanatory variable
Univariable model
P value
Multivariable model*
P valueOR (95% CI) OR (95% CI)
Age (years) 1.02 (0.99 to 1.06) 0.22 0.99 (0.94 to 1.03) 0.54
Females (vs males) 1.18 (0.70 to 1.96) 0.54 1.47 (0.84 to 2.59) 0.18
Multimorbidity† 3.24 (1.93 to 5.44) <0.01 2.08 (1.16 to 3.73) <0.01
Polypharmacy‡ 5.52 (3.10 to 9.86) <0.01 4.81 (2.52 to 9.16) <0.01
*Adjusted for age, sex, multimorbidity, polypharmacy and country. 
†Multimorbidity: defined as the co-occurrence of three or more chronic conditions. 
‡Polypharmacy: defined as five or more regular medicines.
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known osteoporosis and/or fractures. These findings are 
similar to a previous study that used STOPP/START V1 
criteria in a primary care setting in Ireland.28 Prescribing 
of proton pump inhibitors (PPIs) at full therapeutic dose 
for >8 weeks is one of the most common STOPP criteria 
reported in studies but was not reported in this study as 
information relating to drug duration was not available.9 25
The screening process and identification of potential 
participants for this clinical trial differed between coun-
tries and may explain some of the differences in the prev-
alence of PIP and PPOs. In Ireland, clinical trial nurses 
visited individual GP surgeries and with GP approval 
performed a search of the GPs’ databases/notes to identify 
potentially eligible participants. The GP then confirmed 
whether the participant was eligible to participate in 
a screening visit. In Switzerland and the Netherlands, 
potential participants were identified directly from clin-
ical laboratory databases. A list of potential participants 
was sent to their GPs to confirm their eligibility in the 
trial. This screening process was carried out twice by the 
GPs and those who were deemed eligible were invited to 
participate.16 This process may have introduced selection 
bias at GP level as only GPs interested in participating in a 
clinical trial facilitated recruitment and also at the patient 
level as GPs may have excluded more complex patients.
Furthermore, in Ireland and the Netherlands, GPs 
play a gatekeeping role, that is, referral to specialist 
services in general comes from GPs.29 30 Whereas in 
Switzerland, participants can visit medical specialists 
directly if necessary.30 A systematic review and meta-eth-
nographic synthesis of GPs’ experiences on the clinical 
management of multimorbidity identified ‘Disorganisa-
tion and fragmentation of healthcare’ as a key difficulty. 
The authors highlighted that GPs have a more holistic 
view of the patient in contrast to specialists who manage 
disease-specific conditions.31 As Swiss patients can 
visit medical specialists directly if necessary, they may 
receive more non-essential medicines. The prescribing 
process is further complicated if patients attend several 
specialists. Also, if there is a lack of collaborative deci-
sion-making between the patients’ GP and medical 
specialists this could result in a higher prevalence 
of PIP/PPOs among Swiss participants. Therefore, 
enhancing collaborative decision-making between GPs 
and specialists may help to optimise the prescribing of 
older patients. Finally, some countries may have specific 
guidelines for the optimal treatment of conditions. 
These guidelines could differ from the recommenda-
tions in the STOPP/START criteria and could explain 
why some PIP and PPOs were identified in one popula-
tion and not in others.
Clinical and policy implications
Our findings indicate that the overall prevalence of PIP 
using a subset of the STOPP/START V2 criteria across 
three European populations was 12.9%. As PIP is associ-
ated with adverse health outcomes, healthcare providers 
should aim to reduce their prevalence.32 33 A recent 
systematic review of 12 randomised controlled trials 
concluded that various interventions including phar-
macist interventions, clinical decision support systems 
and multifaceted approaches can reduce inappropriate 
prescribing.34 However, it was unclear whether these 
interventions led to clinically significant improvements in 
patient outcomes due to the variability in methodolog-
ical quality of the included studies and the heterogeneity 
of the interventions and outcomes measured.34 Further 
large randomised controlled trials that are methodolog-
ically robust, adhere to the appropriate reporting guide-
lines and have a long duration of follow-up are needed to 
address the efficiency of such interventions to reduce the 
prevalence of PIP/PPOs and improve patient outcomes.
The potential role for medication reviews incorpo-
rating explicit screening tools of PIP for participants 
recruited to clinical trials requires further investigation. 
This may provide trialists with important information 
on the complex nature of prescribing medication regi-
mens in such participants, and how new interventions 
are expected to perform alongside these regimens. In 
addition, the cost of conducting these interventions in 
clinical trial participants should also be explored. Finally, 
screening tools such as the STOPP/START criteria have 
proven to be very beneficial not only in identifying the 
prevalence of PIP/PPOs in studies but also in interven-
tion studies to improve medication appropriateness and 
reduce the risk of adverse drug reactions (ADRs) in older 
people.35 The updated version with the additional criteria 
will help to identify a larger number of PIP and PPO 
Table 3 Results of the univariable and multivariable logistic regression analyses for the association between age, sex, 
multimorbidity and polypharmacy with potential prescribing omissions
Explanatory variable
Univariable model
P value
Multivariable model*
P valueOR (95% CI) OR (95% CI)
Age (years) 1.04 (1.01 to 1.08) <0.01 1.04 (1.00 to 1.07) 0.05
Females (vs males) 1.41 (0.93 to 2.14) 0.11 1.63 (1.04 to 2.57) 0.04
Multimorbidity† 3.04 (1.99 to 4.65) <0.01 4.01 (2.43 to 6.63) <0.01
Polypharmacy‡ 1.30 (0.86 to 1.96) 0.21 0.69 (0.42 to 1.14) 0.144
*Adjusted for age, sex, multimorbidity, polypharmacy and country.
†Multimorbidity: defined as the co-occurrence of three or more chronic conditions.
‡Polypharmacy: defined as five or more regular medicines.
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instances and therefore has a greater potential to reduce 
ADRs and improve other relevant patient outcomes.
strengths and limitations of the study
To the best of our knowledge, this is the first study to esti-
mate and compare the prevalence and type of PIP and 
PPOs using a subset of the STOPP/START V2 criteria 
in community-dwelling older adults across different 
European populations. It also offered an opportunity to 
compare the characteristics of trial participants recruited 
by sites in different countries, and to compare prescribing 
behaviours internationally. International comparisons 
can support or refute arguments for change in health-
care, serve as an additional lens on the state of the 
quality of care provided nationally and can help build the 
evidence base necessary to identify problems and under-
stand changes in the quality of care between countries. 
The TRUST database contains comprehensive informa-
tion on patient demographics, comorbidities and medi-
cation. This facilitated the assessment and measurement 
of prescribing commission and omission for participants 
randomised to the clinical trial. A number of different 
approaches for optimising prescribing appropriateness 
have been published. For example, comprehensive geri-
atric assessment is a time-consuming and resource-inten-
sive strategy to deploy and is more commonly used for 
intervention rather than prevalence studies.36 Therefore, 
STOPP/START was considered the most appropriate and 
feasible tool for this study. The STOPP/START V2 criteria 
were applied by a pharmacist (DOR) who is familiar with 
using this screening tool. To enhance the validity of the 
results, a sample of the data was independently reviewed 
by two healthcare professionals. It was agreed a priori 
to perform the multivariable analysis at the level of the 
patient rather than individual drug as the aim of the study 
was to estimate and compare the prevalence and type of 
PIP and PPOs in the study population.
It is acknowledged that the sample size (n=532) is rela-
tively small; however, the aim was to estimate and compare 
the prevalence and type of PIP and PPOs in a sample of 
patients from three different European countries. The 
study population was based on participants enrolled to 
a clinical trial and may be somewhat different from the 
general population. However, the main inclusion criteria 
for the TRUST trial are quite broad. Second, although 
the data are based on a population of patients with SCH, 
there is no evidence to suggest that this would influence 
their chance of having a PIP or PPO. Although different 
approaches to the collection of medication data were used 
in each country, the authors (and the TRUST consortium 
with regards to safety) believe that all methods are thor-
ough enough to capture all medications. For example, 
studies have highlighted that self-report medications 
are most likely to be congruent with patient records as 
a measure of current medications.37 Although prescrip-
tion drugs were used as proxies to indicate diagnoses, the 
possibility that these drugs may have been used to treat 
other conditions cannot be excluded. It was only possible 
to apply a subset of the STOPP/START V2 criteria as infor-
mation required for some criteria (ie, drug strength, dose 
and duration of prescriptions) was not available in the 
TRUST dataset. For example, the prescribing of PPIs at 
full therapeutic dose for >8 weeks was not reported. This 
may have contributed to an underestimation of the real 
prevalence of PIP in the study. Also, some of the criteria 
could be more explicit. For example, the C1 STOPP crite-
rion ‘long-term aspirin at doses greater than 160 mg per 
day’ does not  define ‘long term’. This requires further 
clarification in future versions of the criteria.38 Although 
Swiss patients can avail of a healthcare plan that requires 
them to visit the GPs first, the GP may not have compre-
hensive information on all the patients’ medicines. This 
includes information on over-the-counter medicines such 
as aspirin and NSAIDs which are included in the STOPP 
criteria and may explain the difference in PIP prevalence 
in these patients. Finally, the TRUST trial concerned 
patients with SCH. It is possible that women with SCH 
were more likely than men to have been treated by 
doctors and therefore not eligible for the trial as doctors 
tend to associate thyroid disease more with women. Also, 
SCH symptoms can overlap with postmenopausal symp-
toms that women report (ie, tiredness, low mood), there-
fore pushing doctors to treat this condition.
COnClusIOns
These study findings highlight that PIP and PPOs are 
prevalent among a sample of community-dwelling older 
people enrolled to a clinical trial in three European coun-
tries. The screening process and identification of poten-
tial participants for this clinical trial differed between the 
countries and may explain some variation in the popu-
lations recruited and prevalence of PIP and PPOs. This 
study is an important first step to justify the need for large 
comparative studies using routine data. This can then 
help to inform policy or the development of appropriate 
interventions on optimising prescribing practices in 
older adults at a national or international level. Further 
research is urgently needed into the impact of system-
level factors as this has important implications for patient 
safety, healthcare provision and economic costs .
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